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Abstract: Anthocyanins are reported to have cardio-protective effects, although their mechanisms
of action remain elusive. We aimed to explore the effects of microbial metabolites common to
anthocyanins and other flavonoids on vascular smooth muscle heme oxygenase-1 (HO-1) expression.
Thirteen phenolic metabolites identified by previous anthocyanin human feeding studies, as well
as 28 unique mixtures of metabolites and their known precursor structures were explored
for their activity on HO-1 protein expression in rat aortic smooth muscle cells (RASMCs).
No phenolic metabolites were active when treated in isolation; however, five mixtures of phenolic
metabolites significantly increased HO-1 protein expression (127.4–116.6%, p ≤ 0.03). The present
study demonstrates that phenolic metabolites of anthocyanins differentially affect HO-1 activity,
often having additive, synergistic or nullifying effects.
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1. Introduction
It is now accepted that microbial metabolites (phenolic and aromatic ring-fission catabolites)
of dietary flavonoids are more bioavailable than their precursor structures [1]. We have previously
reported that anthocyanin metabolites have additive activity in inflammatory systems [2,3], and others
have also demonstrated this in vascular smooth muscle cells [4]. As the mechanisms of action of
flavonoids have remained unresolved for decades, the need to elucidate the activity of phenolic
metabolites has become the focus of recent flavonoid research.
Human feeding studies have shown beneficial effects of flavonoid-rich foods on vascular function,
including blood flow and flow-mediated vasodilation (FMD) [5]. Vascular smooth muscle cells contain
various sources of reactive oxygen species (ROS), such as NAPDH oxidase (NOX), which under
conditions of stress lead to proliferation, migration, and cytokine production, events which are
central to the progression of atherosclerosis [6]. We have previously demonstrated that a number
of anthocyanin metabolites decreased superoxide ions in cultured endothelial cells but had no
effect on the enzyme responsible for their generation, NOX [7]. However, anthocyanin metabolites
increased the expression of oxidant-response protein, heme oxygenase-1 (HO-1), which may induce
antioxidant activity through the production of biliverdin (converted into cellular antioxidant bilirubin),
a by-product of heme degradation [8].
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In the present study, we therefore explored the action of microbial-derived metabolites of
anthocyanins on HO-1 production as a means to rationalise our previous observations. Many of
these metabolites are also common to other precursor flavonoids [1]. The aim of the present study
was to determine the activity of 13 common phenolic metabolites, identified from human feeding
studies [1], relative to six precursor flavonoids (Figure 1), as well as 28 unique mixtures (Table S1),
on HO-1 expression in rat aortic smooth muscle cells (RASMCs).
Figure 1. Structures of (A) flavonoids and (B) metabolites included in treatments. OH, hydroxyl;
Glc, oxygen-linked-glucuronide; OGlu, oxygen-linked glycoside; Sul, sulfate; OCH3, oxygen-linked
methyl group.
2. Results
2.1. Effect of Flavonoids and Their Metabolites on HO-1 Protein Expression
Thirteen phenolic metabolites and six precursor flavonoids were screened for their effect at
10 µM on RASMC HO-1 protein expression after 24 h incubation (Figure 2). HO-1 expression
increased in response to two precursor flavonoids, quercetin (200.87% ± 28.82%, p = 0.009) and
peonidin-3-glucoside (164.05% ± 32.88%, p ≤ 0.001) while no significant activity (p > 0.05) was
observed for single metabolite treatments. Protocatechuic acid (PCA) appeared to have a modest,
but non-significant, effect (121.87% ± 15.47%, p = 0.18).
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Figure 2. Effect of 10 µM flavonoids and phenolic acid metabolites on HO-1 protein expression in
RASMCs. (A) precursor flavonoids; (B) benzoic acid metabolites; (C) protocatechuic acid metabolites;
and (D) vanillic acid metabolites. Data are presented as a percentage of an untreated control (media
only). Filled columns represent vehicle control (0.02% DMSO) and clear columns represent treatments
(10 µM). All columns are representative of the mean ± SD, n = 3 independent samples, ** p ≤ 0.01,
*** p ≤ 0.001 (ANOVA with post hoc Dunnett relative to vehicle control (0.02% DMSO)). 4HBA,
4-hydroxybenzoic acid; BA4G, benzoic acid-4-O-glucuronide; BA4S, benzoic acid-4-sulfate; C3G,
cyanidin-3-O-glucoside; EPI, (−)-epicatechin; HES, hesperetin; IVA, isovanillic acid; IVA3G, isovanillic
acid-3-O-glucuronide; IVA3S, isovanillic acid-3-sulfate; NAR, naringenin; P3G, peonidin-3-O-glucoside;
PCA, protocatechuic acid; PCA3G, protocatechuic acid-3-O-glucuronide; PCA4G, protocatechuic
acid-4-O-glucuronide; PCA3S, protocatechuic acid-3-sulfate; PCA4S, protocatechuic acid-4-sulfate;
QUE, quercetin; VA, vanillic acid; VA4G, vanillic acid-4-O-glucuronide; VA4S, vanillic acid-4-sulfate.
2.2. Effect of Mixtures of Flavonoids and Their Metabolites on HO-1 Expression
Twenty-one mixtures of conjugated and unconjugated phenolic metabolites and seven mixtures
of precursor flavonoids, designed based upon their structural similarity, were screened at cumulative
concentrations of 10 µM for their effect on RASMC HO-1 protein expression after 24 h treatment
(Figure 3). HO-1 expression was increased following treatment with one mixture of precursor
flavonoids, consisting of equimolar concentrations of hesperetin and peonidin-3-O-glucoside
(181.15% ± 13.46%, p ≤ 0.001; Figure 3A). Five mixtures of conjugated and unconjugated flavonoid
metabolites, including: protocatechuic acid + vanillic acid (127.06% ± 5.83%, p = 0.005; Figure 3B);
4-hydroxybenzoic acid + benzoic acid-4-sulfate (129.20% ± 4.00%, p = 0.02; Figure 3C); protocatechuic
acid + protocatechuic acid-3-O-glucuronide (127.43% ± 6.55%, p = 0.001; Figure 3D); protocatechuic
acid + protocatechuic acid-3-O-glucuronide + protocatechuic acid-4-O-glucuronide (116.58% ± 4.77%,
p = 0.03; Figure 3D); vanillic acid + isovanillic acid-3-O-glucuronide (128.02% ± 15.26%, p = 0.009;
Figure 3E), were also active.
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Figure 3. Effect of 10 µM mixtures of flavonoids and phenolic acid metabolites on HO-1 protein
expression in RASMCs. (A) precursor flavonoids; (B) phenolic acids; (C) benzoic acid metabolites;
(D) protocatechuic acid metabolites; (E) vanillic acid metabolites; and (F) all metabolites. Data are
presented as a percentage of an untreated control (media only). Filled columns represent vehicle
control (0.02% DMSO) and clear columns represent treatments (10 µM). All columns are representative
of the mean ± SD, n = 3 independent samples. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 (ANOVA
with post hoc Dunnett relative to vehicle control (0.02% DMSO)). ‘ALL’ is a mixture composed
of 13 conjugated and unconjugated phenolic acids at equimolar concentrations to a cumulative
concentration of 10 µM. 4HBA, 4-hydroxybenzoic acid; BA4G, benzoic acid-4-O-glucuronide;
BA4S, benzoic acid-4-sulfate; C3G, cyanidin-3-O-glucoside; DMSO, dimethyl sulfoxide; EPI,
(−)-epicatechin; HES, hesperetin; IVA, isovanillic acid; IVA3G, isovanillic acid-3-O-glucuronide; IVA3S,
isovanillic acid-3-sulfate; NAR, naringenin; P3G, peonidin-3-O-glucoside; PCA, protocatechuic acid;
PCA3G, protocatechuic acid-3-O-glucuronide; PCA4G, protocatechuic acid-4-O-glucuronide; PCA3S,
protocatechuic acid-3-sulfate; PCA4S, protocatechuic acid-4-sulfate; QUE, quercetin; VA, vanillic acid;
VA4G, vanillic acid-4-O-glucuronide; VA4S, vanillic acid-4-sulfate.
3. Discussion
Bacterial catabolism of flavonoids reduces the bioavailability of the precursor flavonoid,
while producing a number of bioavailable phenolic metabolites [1]. Notwithstanding previous works
suggesting that precursor flavonoids have additive or synergistic effects in combination [2], the present
study of the combined effects of flavonoid metabolites is contemporary, owing to the recent availability
of synthetic standards. The present study is the first to observe the effects of conjugated phenolic
metabolites in combination in vascular smooth muscle cells and suggest that activity of anthocyanins
and other flavonoids may be the result of a cumulative effect of multiple metabolites upregulating
antioxidant-response protein, HO-1. Here, we found that five mixtures consisting of conjugated and
unconjugated phenolic metabolites, one mixture consisting of hesperetin and peonidin-3-O-glucoside
(Figure 3) and two single flavonoid treatments (quercetin and peonidin-3-O-glucoside) (Figure 2)
actively upregulated HO-1 protein in RASMCs. These data suggest that conjugated metabolites of
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flavonoids may not actively increase HO-1 protein in isolation, but act additively or synergistically
in combination.
HO-1 protein was increased in response to five mixtures of phenolic metabolites, which is of
particular interest as the concentration used (10 µM) is within the range of cumulative metabolite
concentrations reported in vivo (0.80–13.18 µM) [9,10]. Keane et al. reported no effect in response to
single metabolite treatments protocatechuic acid (PCA) and vanillic acid (VA) on vascular smooth
muscle cell (VSMC) migration, whereas mixtures of PCA and VA increased VSMC migration,
suggestive of an additive effect [4]. Interestingly, the present study also observed that PCA and
VA in isolation did not significantly increase HO-1 expression, but a combination consisting of 5 µM
of each metabolite (to a cumulative concentration of 10 µM) significantly upregulated HO-1 protein.
This supports the hypothesis that these abundant metabolites act additively on HO-1 expression and
provides a rationale for the lack of effect observed in our previous study where no activity was seen in
endothelial cells in response to PCA or VA in isolation on protein expression [7].
Quercetin significantly induced HO-1 protein expression in the present study, which is in
accordance with previous studies, though it should be noted that quercetin circulates as its
unconjugated, aglycone structure at negligible concentrations post-consumption [11]. Given that
phenolic metabolites exist at much higher concentrations for longer periods of time in the circulation [1],
greater focus should be given to their bioactivity in future studies. Similarly, the anthocyanin
peonidin-3-O-glucoside (P3G) is unstable and rapidly degrades to phenolic acid derivatives at
physiological pH and therefore has low plasma bioavailability [10]. The apparent reduction of activity
between P3G and its B-ring derivative, VA, suggests that the activity of some anthocyanins may be
lost in vivo due to chemical degradation or bacterial catabolism, implying metabolism differentially
impacts the activity of anthocyanins.
The present study has provided a novel insight into the effects of anthocyanin metabolites on
HO-1 in RASMCs, though further work is required to elucidate the underlying mechanisms of these
treatments. Validation of these effects is required at the mRNA level and including Nrf2 localisation
and, ultimately, conformation in animal and human studies. In addition, the use of rat-derived cells
may be seen as a limitation, as the phenotypes and expression levels of cellular proteins may not be
conserved between species, and, even though costs of using human vascular smooth muscle cells are
prohibitive, future work should validate these finding in human cells such as human coronary artery
smooth muscle cells (HCASMCs). In addition, the individual 10 µM treatments utilised were beyond
the physiological concentrations for single precursor flavonoids [10], but necessary as a comparison
to the combination treatments, which were well within physiologically achievable concentrations.
In a previously published study, we observed effects on HO-1 expression in response to 10 µM VA in
human endothelial cells [7]. Therefore, prior to the present study, a handful of compounds were tested
in RASMC at 1, 10, and 100 µM for their effect on HO-1, and 10 µM was identified as most effective
(data not shown) and therefore utilised for the present screen. It is important to note that treatments
may be more active at concentrations below 10 µM, as in a previous study by our group treatment
concentrations as low as 0.19 µM were active [3], and therefore HO-1 expression in response to varied
concentrations should be explored in future studies.
4. Materials and Methods
4.1. Treatments
The conjugated metabolites: benzoic acid-4-O-glucuronide, benzoic acid-4-sulfate, isovanillic
acid-3-O-glucuronide (4-methoxybenzoic acid-3-O-glucuronide), isovanillic acid-3-sulfate (4-methoxybenzoic
acid-3-sulfate), protocatechuic acid-3-O-glucuronide (4-hydroxybenzoic acid-3-O-glucuronide),
protocatechuic acid-4-O-glucuronide (3-hydroxybenzoic acid-4-O-glucuronide), protocatechuic acid-3-sulfate
(4-hydroxybenzoic acid-3-sulfate), protocatechuic acid-4-sulfate (3-hydroxybenzoic acid-4-sulfate),
vanillic acid-4-O-glucuronide (3-methoxybenzoic acid-4-O-glucuronide), and vanillic acid-4-sulfate
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(3-methoxybenzoic acid-4-sulfate), were previously synthesised at the University of St. Andrews (UK) [12].
Flavonoids (cyanidin-3-O-glucoside, (−)-epicatechin, hesperetin, naringenin, and quercetin) and
unconjugated phenolic acids: 4-hydroxybenzoic acid, protocatechuic acid (3,4-dihydroxybenzoic acid),
and vanillic acid (4-hydroxy-3-methoxybenzoic acid), were obtained from Sigma Aldrich (Dorset, UK),
with the exception of peonidin-3-O-glucoside (Extrasynthase, Genay, France). Stock solutions of all
compounds were prepared in 100% DMSO at 200 mM, with the exception of cyanidin-3-O-glucoside
and peonidin-3-O-glucoside, which were prepared at 40 mM, and sulfate-conjugated phenolic acids at
25 mM in 50% DMSO (50% PBS) to maintain stability whilst reducing final DMSO concentrations
in working solutions. All stock solutions were stored at 80 ◦C. Working solutions of individual
treatments were added to supplemented media at 10 µM concentrations immediately prior to
treatment. Treatments containing mixtures of compounds consisted of equimolar concentrations of the
constituent treatment compounds (Table S1) to a cumulative concentration of 10 µM. For example,
a combination comprising four constituents required 2.5 µM of each, equating to a total concentration
of 10 µM. No treatments were cytotoxic as established utilising the WST-1 cytotoxicity assay (Roche,
West Sussex, UK) (data not shown).
4.2. Cell Culture
Cryopreserved, second passage, pooled Clonetics rat aortic smooth muscle cells (RASMCs)
from adult Sprague Dawley (Lonza Biologics, Manchester, UK), were maintained in Dulbecco’s
modified Eagle’s medium: F12 (DMEM) containing 0.1% gentamycin/amphotericin and 20% FBS
(Lonza Biologics, Manchester, UK). Cells were used between passages 3 and 6.
4.3. HO-1 Protein Expression
RASMC were seeded at 300,000 cells/well in fibronectin-coated 6-well plates. Supplemented
media was replaced by serum-free media 24 h prior to experiment commencement. Cells were treated
with media only (untreated control), 10 µM treatment, 0.02% DMSO (vehicle control), and incubated
for 24 h at 37 ◦C, 5% CO2, in a humidified atmosphere. Cells were washed 3x with PBS and cells
lysed with Extraction Reagent Buffer (Enzo Lifesciences, City, UK) and stored at −80 ◦C until required,
undergoing one freeze-thaw cycle. HO-1 protein in cell lysates was determined by use of Rat Hmox-1
ELISA Kits (Enzo Lifesciences, Exeter, UK) according to the manufacturer’s instructions. HO-1 protein
concentrations were normalised to the total cell protein content using the Pierce Protein BCA protein
assay (Thermo Fisher Scientific, Loughborough, UK).
4.4. Data Analysis
HO-1 protein values were presented as a percentage of an untreated control (media only) and
reported as the mean ± standard deviation of 3 independent samples. Treatment effects were
determined relative to the vehicle control (0.02% DMSO) and established by one-way analysis of
variance (ANOVA) with post hoc Dunnett. Analyses were conducted using SPSS for Windows
(version 22.0; IBM, New York, NY, USA). Data were considered significant where p ≤ 0.05.
5. Conclusions
In conclusion, the present study has demonstrated that the bioactivity of common phenolic
metabolites is increased when in combination, indicating additive or synergistic effects.
Supplementary Materials: The following are available online at http://www.mdpi.com/1420-3049/23/4/898/s1:
Table S1: Combination treatment constituents and relative concentrations.
Acknowledgments: We thank Qingzhi Zhang, Saki Raheem, and David O’Hagan of the University of St Andrews
(UK) who undertook the chemical synthesis of phenolic conjugate standards and the late Nigel Botting (also of
the University of St. Andrews, UK) who helped establish this research collaboration, including the design of the
synthesis project objectives. This study was supported by funding from the UK Biotechnology and Biological
Molecules 2018, 23, 898 7 of 7
Sciences Research Council Diet and Health Research Industry Club (BBSRC-DRINC; BB/I006028/1). I.R.R. was
funded by a BBSRC-DRINC Post-Doctoral Fellowship grant (BB/I006028/1).
Author Contributions: C.D.K. and M.O.C. conceived and managed the project. E.F.W., I.R.-R., C.K., and M.O.C.
designed the culture experiments and methodology. I.R.-R. conducted the cell culture work and E.F.W. collected
and graphed the data. C.K., M.O.C., I.R.-R., and E.F.W. contributed to the analysis and interpretation of the data.
E.F.W. and C.K. drafted the initial manuscript and all authors reviewed and approved the final content.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Kay, C.D.; Pereira-Caro, G.; Ludwig, I.A.; Clifford, M.N.; Crozier, A. Anthocyanins and Flavanones Are More
Bioavailable than Previously Perceived: A Review of Recent Evidence. Annu. Rev. Food Sci. Technol. 2017, 8,
155–180. [CrossRef] [PubMed]
2. Di Gesso, J.L.; Kerr, J.S.; Zhang, Q.; Raheem, S.; Yalamanchili, S.K.; O’Hagan, D.; Kay, C.D.; O’Connell, M.A.
Flavonoid metabolites reduce tumor necrosis factor-alpha secretion to a greater extent than their precursor
compounds in human THP-1 monocytes. Mol. Nutr. Food Res. 2015, 59, 1143–1154. [CrossRef] [PubMed]
3. Warner, E.F.; Smith, M.J.; Zhang, Q.; Raheem, K.S.; O’Hagan, D.; O’Connell, M.A.; Kay, C.D. Signatures
of anthocyanin metabolites identified in humans inhibit biomarkers of vascular inflammation in human
endothelial cells. Mol. Nutr. Food Res. 2017, 61. [CrossRef] [PubMed]
4. Keane, K.M.; Bell, P.G.; Lodge, J.K.; Constantinou, C.L.; Jenkinson, S.E.; Bass, R.; Howatson, G. Phytochemical
uptake following human consumption of Montmorency tart cherry (L. Prunus cerasus) and influence of
phenolic acids on vascular smooth muscle cells in vitro. Eur. J. Nutr. 2016, 55, 1695–1705. [CrossRef]
[PubMed]
5. Hooper, L.; Kroon, P.A.; Rimm, E.B.; Cohn, J.S.; Harvey, I.; Le Cornu, K.A.; Ryder, J.J.; Hall, W.L.; Cassidy, A.
Flavonoids, flavonoid-rich foods, and cardiovascular risk: A meta-analysis of randomized controlled trials.
Am. J. Clin. Nutr. 2008, 88, 38–50. [CrossRef] [PubMed]
6. Lusis, A.J. Atherosclerosis. Nature 2000, 407, 233–241. [CrossRef] [PubMed]
7. Edwards, M.; Czank, C.; Woodward, G.M.; Cassidy, A.; Kay, C.D. Phenolic metabolites of anthocyanins
modulate mechanisms of endothelial function. J. Agric. Food Chem. 2015, 63, 2423–2431. [CrossRef] [PubMed]
8. Gozzelino, R.; Jeney, V.; Soares, M.P. Mechanisms of cell protection by heme oxygenase-1. Annu. Rev.
Pharmacol. Toxicol. 2010, 50, 323–354. [CrossRef] [PubMed]
9. Czank, C.; Cassidy, A.; Zhang, Q.; Morrison, D.J.; Preston, T.; Kroon, P.A.; Botting, N.P.; Kay, C.D. Human
metabolism and elimination of the anthocyanin, cyanidin-3-glucoside: A (13)C-tracer study. Am. J. Clin. Nutr.
2013, 97, 995–1003. [CrossRef] [PubMed]
10. De Ferrars, R.M.; Czank, C.; Zhang, Q.; Botting, N.P.; Kroon, P.A.; Cassidy, A.; Kay, C.D. The pharmacokinetics of
anthocyanins and their metabolites in humans. Br. J. Pharmacol. 2014, 171, 3268–3282. [CrossRef] [PubMed]
11. Nabavi, S.F.; Russo, G.L.; Daglia, M.; Nabavi, S.M. Role of quercetin as an alternative for obesity treatment:
You are what you eat! Food Chem. 2015, 179, 305–310. [CrossRef] [PubMed]
12. Zhang, Q.; Raheem, K.S.; Botting, N.P.; Slawin, A.M.Z.; Kay, C.D.; O’Hagan, D. Flavonoid metabolism:
The synthesis of phenolic glucuronides and sulfates as candidate metabolites for bioactivity studies of dietary
flavonoids. Tetrahedron 2012, 68, 4194–4201. [CrossRef]
Sample Availability: Samples are not available from the authors.
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
